Fatty liver, also known as fatty liver disease (FLD), is a reversible condition where large vacuoles of triglyceride fat accumulate in liver cells via the process of steatosis (i.e. abnormal retention of lipids within a cell).
A significant genome-wide association study on the nonalcoholic fatty liver disease (NAFLD) has just been published in Nature Genetics by researchers from Amgen subsidiary deCODE Genetics.
A long-running debate in gastroenterology has been settled by WEHI researchers who have shown that prevalent liver diseases are not caused by inflammatory cell death as previously believed.
The immune system may attack the liver when fat builds up there. The chemical that triggers these responses has been discovered by Weill Cornell Medicine researchers in a recent study, and this information helps to explain the dynamics of liver damage that can accompany type 2 diabetes and obesity.
A multidisciplinary group of researchers at the University of California San Diego School of Medicine have advanced investigations into the genetic causes of NAFLD in children.
First product within new ‘in-a-box’ range, which harnesses next-generation, human-relevant Liver-on-a-Chip technology to improve the accuracy and efficiency of NASH drug discovery.
Non-alcoholic fatty liver disease (NAFLD), commonly known as fatty liver disease, is a prevalent disease frequently seen in obese people. Having high fat content in the liver is detrimental as it is strongly associated with severe health problems like diabetes, high blood pressure, and liver cancer.
In a breakthrough discovery, scientists from The University of Texas Health Science Center at San Antonio today reported that inhibiting a liver enzyme in obese mice decreased the rodents' appetite, increased energy expenditure in adipose (fat) tissues and resulted in weight loss.
A new scientific review, published in Nutrients, highlights coffee's effects on digestion and the gut, and its impact on organs involved in digestion.
Professor Yuichi Oike and his group of researchers recently produced a peptide vaccine that mitigates conditions of dyslipidemia.
Non-alcoholic fatty liver disease (NAFLD) is the accumulation of fat in the liver unrelated to alcohol abuse or other liver diseases.
Research demonstrated that obese individuals with active brown fat possess a healthier metabolism and utilize more energy than obese people without.
For the first time, DNA mutations in liver cells have been identified that impact metabolism and insulin sensitivity in patients with liver disease.
Results of national research pinpointed potential biomarkers that could ultimately be employed for the diagnosis of progressive stages of liver disease.
Time-restricted eating (TRE) is a dietary regimen in which eating is restricted to particular hours. It has received great attention in weight-loss circles.
RNA molecules while carrying genetic instructions from DNA to the protein-making machinery of cells could help guard against non-alcoholic fatty liver.
Chronic alcohol abuse and hepatitis can injure the liver and lead to fibrosis, the buildup of collagen and scar tissue. As a potential approach to treating liver fibrosis, University of California San Diego School of Medicine researchers and their collaborators are looking for ways to stop liver cells from producing collagen.
Scientists discovered 22 lipids in the blood plasma of schizophrenia patients that were linked to slower symptom improvement over time.
Researchers from the EMBL and the German Cancer Research Center (DKFZ) demonstrated a new technique to create metabolic profiles of individual cells.
Non-alcoholic fatty liver disease (NAFLD) is the most common cause of chronic liver disease worldwide. NAFLD patients are at higher risk of developing Non-alcoholic steatohepatitis (NASH), which causes severe and chronic liver inflammation, fibrosis and liver damage.
A team of researchers led by Thaddeus Stappenbeck discovered that a high-fat, high-sugar diet relates to reduced intestinal immune cell activity in mice.